Antibody

263개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved263 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleWest China HospitalPhase 2

Tagitanlimab (Tagitanlimab)

Resectable Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell C

#ResectableHeadandNeckSquamousCel#Antibody#Phase2#monoclonal-antibody#West
Trials 1Status Recruiting
AntibodyLimited DatastaleRuijin HospitalPhase 2

Tirelizumab (Tirelizumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Ruijin
Trials 1Status Recruiting
AntibodyLimited DatastaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#Non-squamousNon-smallCellLungCan+2
Trials 1Status Active
AntibodyLimited DatastaleChugai PharmaceuticalPhase 1

Tocilicumab (Tocilicumab)

Hepatocellular Carcinoma (HCC) · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase1#monoclonal-antibody#Chugai
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tocilizumab before CAR-T cell infusion (Tocilizumab before CAR-T cell infusion)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab combine with Rituximab (Toripalimab combine with Rituximab)

Diffuse Large B-cell Lymphoma; Rituximab · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#Rituximab+1
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab, Rituximab (Toripalimab, Rituximab)

Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#monoclonal-antibody#High-gradeB-cellLymphoma+1
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

MEDI4736 (Tremelimumab Plus Durvalumab, Tremelimumab Plus Durvalumab (MEDI4736))

Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase2#monoclonal-antibody#UnresectableHepatocellularCarcin+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab immunotherapy (Tremelimumab immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tucidinostat (Tucidinostat, Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, chidamide)

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#EsophagealSquamousCellCancer+3
Trials 1Status Active
AntibodyLimited DatastaleCentre Hospitalier Universitair…Phase 2

nivolumab (Opdivo, UCPVax + Nivolumab)

Advanced Non-small Cell Lung Cancer · Advanced Non-small Cell Lung Cancer

#AdvancedNon-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Centre
Trials 1Status Active
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 3

Uliledlimab (Uliledlimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#TJ
Trials 1Status Recruiting
AntibodyLimited DatastaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Recruiting
AntibodyLimited DatastaleFudan UniversityPhase 2

Vebrekotuzumab (Vebrekotuzumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Fudan
Trials 1Status Recruiting
AntibodyLimited DatastaleInflaRx GmbHPhase 2

Vilobelimab (Vilobelimab)

SCC - Squamous Cell Carcinoma of Skin · SCC - Squamous Cell Carcinoma of Skin

#SCC-SquamousCellCarcinomaofSkin#Antibody#Phase2#monoclonal-antibody#InflaRx
Trials 1Status Discontinued
AntibodyLimited DatastaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 2

pembrolizumab (Keytruda, XmAb18087 ± Pembrolizumab)

Merkel Cell Carcinoma; Small Cell Lung Cancer · Merkel Cell Carcinoma

#MerkelCellCarcinoma#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb819 (XmAb819)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Xencor
Trials 1Status Recruiting

12 / 14 pages

← PreviousNext →